January 9, 2023 / Moderna, Inc. (NASDAQ:MRNA),announced updates on its industry-leading mRNA pipeline.
2022 COVID-19 vaccine sales of approximately $18.4 billion (unaudited).
Reiterating 2023 expected minimum COVID-19 vaccines sales of approximately $5.0 billion from confirmed Advance Purchase Agreements and 2022 contract deferrals.
Potential additional contracts in the United States, Europe, Japan, and other key markets.
About Moderna (NASDAQ:MRNA)
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow theauthorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.